<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036279</url>
  </required_header>
  <id_info>
    <org_study_id>R11014-1</org_study_id>
    <nct_id>NCT04036279</nct_id>
  </id_info>
  <brief_title>NANOS Neck Preserving Hip Stem</brief_title>
  <acronym>NANOS</acronym>
  <official_title>A Prospective, Multicenter, Clinical Outcome Study of the NANOS Neck Preserving Stem in Patients With Degenerative Hip Joint Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew Orthopaedics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the long-term safety and effectiveness of the
      NANOS neck preserving stem in terms of radiographic and clinical performance as well as
      short-, mid- and long-term survivorship
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this multicenter clinical observation is to validate short-, mid-, and long-term
      outcome (efficacy and safety) of the NANOS neck preserving hip stem.

      Effectiveness Measures:

        -  Evaluation of function, range of motion (ROM) and pain as assessed by Harris Hip Score,
           HOOS Score [4-6], UCLA Activity Rating [7]

        -  Radiographic changes as defined by radiolucent lines, osteolysis, hypo- and hypertrophy,
           implant loosening or migration

      Safety evaluations:

        -  Intra- and peri-operative device-related adverse events (AE) and complications up to
           discharge

        -  Postoperative AE up to 10 years
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long term survivorship of Nanos</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">130</enrollment>
  <condition>Primary Osteoarthritis</condition>
  <condition>Secondary Osteoarthritis</condition>
  <condition>Dysplasia Osteoarthritis</condition>
  <condition>Avascular Femoral Neck Necrosis</condition>
  <condition>Post-Traumatic Femoral Neck Necrosis</condition>
  <condition>Intact Femoral Neck With Good Bone Quality</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Hip Arthroplasty</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic for Orthopedics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria:

          -  Patient requires Primary total hip replacement (THR) to the affected side, unilateral
             or bilateral. Bilateral only if &gt;3 months after the first THR

          -  Patient agreed to participate in the MCO study by signing the Informed Consent form.

          -  Age of patient at date of surgery 18 to 65 years

          -  Patient is likely to comply with study follow-up requirements

        Exclusion criteria:

          -  Previously failed endoprosthesis and /or THR components in relevant hip

          -  Patient has proven osteoporosis

          -  Pronounced coxa valga with a femoral neck angle &gt; 145º

          -  Pronounced coxa vara with a femoral neck angle &lt; 125º

          -  History of infection in the affected joint; systemic infections

          -  Grossly insufficient femoral or acetabular bone stock in the involved hip where a
             revision cup is indicated

          -  Spinal disease with neurologic movement disorders

          -  Alcoholism or addictive disorders

          -  ASA score is 3 or 4

          -  Body mass index (BMI) &gt; 30

          -  Patient is pregnant or being pregnant during follow up intervals

          -  Patients understanding of the language is insufficient for understanding the Patient
             Information and Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Turgay Efe, Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phillips University Marburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinay Bhal</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Clinical Strategy Lead</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Marburg, Orthopedics and Rheumatology</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Wojewodzki Spital</name>
      <address>
        <city>Piekary Śląskie</city>
        <zip>41-940</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NANOS</keyword>
  <keyword>Hip</keyword>
  <keyword>Neck Preserving Stem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

